Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$6.45
-4.3%
$7.44
$6.33
▼
$14.51
$422.41M1.81841,692 shs1.11 million shs
Mesoblast Limited stock logo
MESO
Mesoblast
$10.89
-2.6%
$13.96
$10.87
▼
$21.50
$1.42B2.21233,317 shs192,703 shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$142.85
-2.0%
$142.96
$72.22
▼
$179.95
$2.09B-0.21261,602 shs192,667 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$26.14
-2.7%
$27.21
$21.52
▼
$31.97
$1.80B1.32789,090 shs738,813 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
-0.30%-1.89%-12.01%-27.99%-41.54%
Mesoblast Limited stock logo
MESO
Mesoblast
-3.95%-14.66%-9.91%-34.24%-24.71%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-0.55%-4.84%+17.63%+2.63%+50.42%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+3.15%+1.47%-0.19%-6.31%+18.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$6.45
-4.3%
$7.44
$6.33
▼
$14.51
$422.41M1.81841,692 shs1.11 million shs
Mesoblast Limited stock logo
MESO
Mesoblast
$10.89
-2.6%
$13.96
$10.87
▼
$21.50
$1.42B2.21233,317 shs192,703 shs
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$142.85
-2.0%
$142.96
$72.22
▼
$179.95
$2.09B-0.21261,602 shs192,667 shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$26.14
-2.7%
$27.21
$21.52
▼
$31.97
$1.80B1.32789,090 shs738,813 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
-0.30%-1.89%-12.01%-27.99%-41.54%
Mesoblast Limited stock logo
MESO
Mesoblast
-3.95%-14.66%-9.91%-34.24%-24.71%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-0.55%-4.84%+17.63%+2.63%+50.42%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+3.15%+1.47%-0.19%-6.31%+18.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.50
Moderate Buy$15.18135.38% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
2.33
Hold$39.00258.13% Upside
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
2.94
Moderate Buy$214.8650.41% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.79
Moderate Buy$43.2565.46% Upside

Current Analyst Ratings Breakdown

Latest ARVN, ZYME, PVLA, and MESO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Reiterated RatingBuy$246.00
11/16/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Initiated CoverageOutperform$228.00
11/13/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetMarket Outperform$32.00 ➝ $39.00
11/11/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$39.00 ➝ $44.00
11/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$34.00 ➝ $39.00
11/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$35.00 ➝ $36.00
11/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$55.00 ➝ $56.00
11/9/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
DowngradeStrong-Buy ➝ Hold
11/9/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Boost Price TargetBuy$232.00 ➝ $243.00
11/6/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Initiated CoverageStrong-Buy
11/6/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Boost Price TargetOutperform$210.00 ➝ $232.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$262.60M1.61N/AN/A$7.85 per share0.82
Mesoblast Limited stock logo
MESO
Mesoblast
$120.25M11.78N/AN/A$4.38 per share2.49
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
$42.81M48.78N/AN/A$13.54 per share10.55
Zymeworks Inc. stock logo
ZYME
Zymeworks
$105.96M17.03N/AN/A$3.74 per share6.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$80.80M-$0.24N/AN/AN/A-3.45%-2.00%-1.43%N/A
Mesoblast Limited stock logo
MESO
Mesoblast
-$57.50MN/AN/A30.25N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$41.72M-$5.50N/AN/AN/AN/A-44.44%-36.75%N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$81.13M$0.5250.2796.81N/A16.10%22.23%7.14%N/A

Latest ARVN, ZYME, PVLA, and MESO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
$2.27$2.28+$0.01$2.28$227.40 million$512.92 million
11/5/2026Q3 2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
-$1.78-$1.70+$0.08-$1.70$0.02 millionN/A
11/3/2026Q3 2026
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.9177-$0.82+$0.0977-$0.82$12.39 million$0.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
8.39
8.39
Mesoblast Limited stock logo
MESO
Mesoblast
0.19
2.43
2.09
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
N/A
16.01
16.01
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
3.30
3.30

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
40.11%
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
7.30%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
17.20%
Zymeworks Inc. stock logo
ZYME
Zymeworks
37.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
24665.49 million60.71 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
108130.13 million105.67 millionOptionable
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
2914.62 million12.10 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
26469.03 million42.99 millionOptionable

Recent News About These Companies

Zymeworks (NASDAQ:ZYME) Shares Up 4.9% - What's Next?
Zymeworks Announces Participation in Upcoming Investor Conferences
Insider Selling: Zymeworks (NASDAQ:ZYME) Insider Sells $1,036,047.87 in Stock
Zymeworks (NASDAQ:ZYME) Shares Gap Up After Analyst Upgrade
Zymeworks (NASDAQ:ZYME) Board of Directors Approves Stock Repurchase Plan
Zymeworks (NASDAQ:ZYME) to Buy Back $200 million in Stock
Zymeworks Inc. authorizes a Buyback Plan.
Zymeworks (NASDAQ:ZYME) Shares Gap Up on Analyst Upgrade
Zymeworks (NASDAQ:ZYME) Price Target Raised to $44.00
HC Wainwright Reduces Earnings Estimates for Zymeworks
Citi Sticks to Its Buy Rating for Zymeworks (ZYME)
Zymeworks (NASDAQ:ZYME) Price Target Raised to $39.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arvinas stock logo

Arvinas NASDAQ:ARVN

$6.45 -0.29 (-4.30%)
Closing price 03:58 PM Eastern
Extended Trading
$6.46 +0.01 (+0.16%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$10.89 -0.29 (-2.59%)
Closing price 04:00 PM Eastern
Extended Trading
$10.92 +0.02 (+0.23%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Palvella Therapeutics stock logo

Palvella Therapeutics NASDAQ:PVLA

$142.85 -2.92 (-2.00%)
Closing price 04:00 PM Eastern
Extended Trading
$142.71 -0.14 (-0.10%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Zymeworks stock logo

Zymeworks NASDAQ:ZYME

$26.14 -0.72 (-2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$26.16 +0.02 (+0.06%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.